呋喹替尼治疗晚期结直肠癌的疗效及全因死亡的危险因素分析  

The efficacy of fruquintinib in the treatment of advanced colorectal cancer and analysis of risk factorsforall-causedeath

作　　者：周海荣[1] 高振远 吴骁 Zhou Hairong;Gao Zhenyuan;Wu Xiao(Department of Oncology,the First Afiliated Hospital of Bengbu Medical College,Bengbu 233000,China)

机构地区：[1]蚌埠医学院第一附属医院肿瘤科,蚌埠233000

出　　处：《中国医师进修杂志》2023年第9期821-825,共5页Chinese Journal of Postgraduates of Medicine

基　　金：蚌埠医学院自然科学重点项目(2020byzd144)。

摘　　要：目的:探讨呋喹替尼治疗晚期结直肠癌的疗效,并分析影响呋喹替尼治疗全因死亡的危险因素。方法:回顾性分析蚌埠医学院第一附属医院2020年12月至2022年4月82例晚期结直肠癌患者的临床资料。记录患者的基本临床资料、疗效、不良反应;患者随访至2022年10月,记录全因死亡情况。采用多因素Logistic回归分析影响呋喹替尼治疗晚期结直肠癌患者全因死亡的危险因素。结果:治疗后,晚期结直肠癌患者部分缓解9例,疾病稳定42例,疾病进展31例,客观缓解率为10.98%(9/82),疾病控制率为62.20%(51/82)。不良反应发生率为75.61%(62/82),以高血压和手足综合征多见。至随访结束,全因死亡19例,存活63例。全因死亡患者体质量指数(BMI)≥24 kg/m 2、淋巴结转移、肿瘤位于右半结肠和乳酸脱氢酶>200 U/L发生率明显高于存活患者[36.51%(23/63)比16/19、39.68%(25/63)比13/19、44.44%(28/63)比15/19和41.27%(26/63)比14/19],差异有统计学意义( P<0.01或<0.05);两者性别构成、年龄、吸烟史、高血压和术后并发症比较差异无统计学意义( P>0.05)。多因素Logistic回归分析结果显示,BMI≥24 kg/m^(2)、淋巴结转移、肿瘤位于右半结肠和乳酸脱氢酶>200 U/L是影响呋喹替尼治疗晚期结直肠癌患者全因死亡的独立危险因素( OR = 9.275、3.293、4.687和3.985,95% CI 2.440~35.265、1.106~9.806、1.398~15.715和1.277~12.430, P<0.01或<0.05)。 结论:呋喹替尼治疗晚期结直肠癌效果理想,BMI≥24 kg/m 2、淋巴结转移、肿瘤位于右半结肠和乳酸脱氢酶>200 U/L是影响呋喹替尼治疗晚期结直肠癌患者全因死亡的独立危险因素。Objective To investigate the efficacy of fruquintinib in the treatment of advanced colorectal cancer,and to analyze the risk factors for all-cause death of fruquintinib.MethodssThe clinical data of 82 patients with advanced colorectal cancer in the First Affiliated Hospital of Bengbu Medical College from December 2020 to April 2022 were retrospectively analyzed.The basic clinical data,efficacy and adverse reactions were recorded.The patients were followed up to October 2022,and all-cause death was recorded.Multivariate Logistic regression was used to analyze the risk factors of allcause death in patients with advanced colorectal cancer treated with fruquintinib.Results After treatment,partial remission was found in 9 cases,stable disease in 42 cases,disease progression in 31 cases.The objective remission rate was 10.98%(9/82),and the disease control rate was 62.20%(51/82).The incidence of adverse reactions was 75.61%(62/82),mainly hypertension and hand-foot syndrome.By the end of follow-up,19 patients died and 63 survived.The incidences of body mass index(BMI)≥24 kg/m²,lymph node metastasis,tumor located in the right colon and lactate dehydrogenase>200 U/L in allcause death patients were significantly higher than those in survival patients:36.51%(23/63)vs.16/19,39.68%(25/63)vs.13/19,44.44%(28/63)vs.15/19 and 41.27%(26/63)vs.14/19,and there were statistical differences(P<0.01 or<0.05);there were no statistical differences in gender composition,age,smoking history,hypertension and postoperative complications between the two groups(P>0.05).Multivariate Logistic regression analysis result showed that BMI≥24 kg/m',lymph node metastasis,tumor located in the right colon and lactate dehydrogenase>200 U/L were independent risk factors for allcause death in patients with advanced colorectal cancer treated with fruquintinib(OR=9.275,3.293,4.687 and 3.985;95%CI 2.440 to 35.265,1.106 to 9.806,1.398 to 15.715 and 1.277 to 12.430;P<0.01 or<0.05).Conclusions Fruquintinib is effective in the treatment of advanced colorectal

关 键 词：结直肠肿瘤 治疗结果 死亡 危险因素 呋喹替尼 

分 类 号：R735.34[医药卫生—肿瘤]